Sandoz Will Wait A Decade On Amantadine
Patent-Litigation Settlement Permits 2030 Launch
Sandoz will be able to launch a generic of Adamas’ amantadine-based Gocovri brand in the US from March 2030. But a patent-litigation settlement permits an earlier entry if sales of the dyskinesia brand decline.
You may also be interested in...
Newly public Aligos will team with Merck & Co. on oligonucleotide therapies for NASH. Maze Therapeutics launches ophthalmology and CV-focused spinouts with Alloy and BridgeBio.
Germany’s off-patent industry association, Pro Generika, is finding ample support for its position that by awarding tender contracts to exclusive suppliers, health insurance funds are contributing to drug shortages in the country.
A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.